Regeneron Pharmaceuticals, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Tarrytown, NY
REGN chart
What traders are saying about $REGN
Latest postsRegeneron Pharmaceuticals, Inc. news
- iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Nov. 9
Yahoo Finance ·
- Is Regeneron Pharmaceuticals (REGN) Expensive On Promising CIDEBsiRNA Liver Disease Data?
Simply Wall St ·
- Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction
Yahoo Finance ·
- Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
247wallst.com ·
- Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%
marketbeat.com ·
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH - Slideshow (NASDAQ:REGN) 2026-11-10
Seeking Alpha ·
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
Yahoo Finance ·
- 3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
247wallst.com ·
- Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
Yahoo Finance ·
- Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva
Yahoo Finance ·
- 24,392 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Pictet Asset Management Holding SA
MarketBeat ·
- Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery
Yahoo Finance ·
Regeneron Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 |
| Total assets (year end) | $40.56B | $37.76B | $33.08B | $29.21B |
| Cash and equivalents (year end) | $3.12B | $2.49B | $2.73B | $3.11B |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Regeneron Pharmaceuticals, Inc.
- Ticker
- REGN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Tarrytown, NY
- Incorporated in
- NY
- Fiscal year end
- December 31
- SEC CIK
- 872589
- Former names
- REGENERON PHARMACEUTICALS INC
Frequently asked questions
What exchange is Regeneron Pharmaceuticals, Inc. listed on?
Regeneron Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol REGN.
What industry is Regeneron Pharmaceuticals, Inc. in?
Regeneron Pharmaceuticals, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Regeneron Pharmaceuticals, Inc. headquartered?
Regeneron Pharmaceuticals, Inc.'s business address on file with the SEC is in Tarrytown, NY.
When does Regeneron Pharmaceuticals, Inc.'s fiscal year end?
Regeneron Pharmaceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Regeneron Pharmaceuticals, Inc. report?
Regeneron Pharmaceuticals, Inc. reported $14.34B in revenue for calendar year 2025, according to its SEC filings.